GLP-1 & Peptide Resource Hub
GLP-1 medicines, peptide therapies, emerging incretin drugs and research peptides explained in one evidence-focused library.
GLP-1 drugs have moved from a diabetes niche into one of the most important areas of modern metabolic medicine. At the same time, interest has expanded into amylin analogs, GIP/GLP-1 combinations, triple agonists, growth-hormone-related peptides, regenerative peptides and other experimental compounds.
This resource hub is designed to help readers distinguish between approved medicines, investigational therapies, and research-use compounds. Evidence, regulatory status and safety should always be evaluated for the specific molecule, indication, dose, route of administration and patient population.
Start Here: Find the Right GLP-1 or Peptide Topic
💉 GLP-1 Weight Management
Learn how semaglutide, liraglutide and tirzepatide differ, what the clinical evidence shows, and how treatment decisions are normally individualized.
💪 GLP-1 & Muscle
Explore lean mass, protein intake, resistance training, body composition and strategies studied during substantial weight loss.
🔬 GLP-1 Research Library
A growing evidence library covering clinical trials, cardiovascular outcomes, diabetes, obesity, metabolic health, adverse effects and emerging indications.
1. GLP-1 Medicines
GLP-1 receptor agonists mimic or activate the receptor for glucagon-like peptide-1. Depending on the drug and indication, these medicines can improve glucose regulation, delay gastric emptying and influence appetite and energy intake.
.png)
| Medicine | Class | Major clinical use areas | What to research |
|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist | Type 2 diabetes; obesity/overweight indications depending on product and jurisdiction | Weight loss, cardiovascular outcomes, gastrointestinal effects, muscle/lean mass, dosing, oral vs injectable formulations |
| Liraglutide | GLP-1 receptor agonist | Type 2 diabetes; obesity/overweight indications depending on product and jurisdiction | Weight management, diabetes, cardiovascular risk, tolerability, comparison with newer agents |
| Dulaglutide | GLP-1 receptor agonist | Type 2 diabetes and cardiovascular risk reduction in specified populations | Cardiovascular outcomes, glucose lowering, tolerability and long-term diabetes management |
| Exenatide | GLP-1 receptor agonist | Type 2 diabetes | Short- vs extended-release formulations, glucose control and historical role in incretin therapy |
| Lixisenatide | GLP-1 receptor agonist | Type 2 diabetes; product availability varies | Glucose lowering, gastric emptying and combination therapy |
| Tirzepatide | Dual GIP/GLP-1 receptor agonist | Type 2 diabetes; obesity/overweight indications depending on product and jurisdiction | Dual incretin biology, weight loss, cardiovascular outcomes, sleep apnea, metabolic disease and adverse effects |
↔ Swipe the table sideways to see all columns on mobile.
FDA materials identify semaglutide, liraglutide, dulaglutide, exenatide and lixisenatide among GLP-1 receptor agonists, while tirzepatide targets both GIP and GLP-1 receptors. Product approvals and indications should always be checked against the current local label.
Semaglutide
Semaglutide is one of the most extensively studied incretin medicines and is available in multiple formulations and brands. Research topics include obesity, type 2 diabetes, cardiovascular outcomes, gastrointestinal effects, body composition and treatment continuation or discontinuation.
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist rather than a conventional single-receptor GLP-1 agonist. It has become a central reference point for comparisons involving next-generation obesity and metabolic medicines.
Liraglutide & Dulaglutide
These established GLP-1 medicines remain important for understanding the evolution of incretin treatment, especially when comparing duration of action, administration schedules, clinical indications and cardiovascular evidence.
2. Beyond GLP-1: The Next Generation of Incretin & Metabolic Peptides
The next wave of obesity research increasingly involves combinations or multi-receptor agonists rather than simply stronger versions of traditional GLP-1 drugs.
Retatrutide
A triple agonist targeting GIP, GLP-1 and glucagon receptors. As of September 2026, it remained investigational rather than an approved medicine, with Phase 3 development and regulatory submissions underway.
Cagrilintide
A long-acting amylin analog being studied as a standalone metabolic therapy and as part of combination strategies.
CagriSema
A fixed-dose combination of cagrilintide and semaglutide designed to combine amylin and GLP-1 biology. Approval status must be checked because the product remained investigational in the September 2026 development landscape.
Zenagamtide / Amycretin
A long-acting unimolecular GLP-1 and amylin receptor agonist being developed in oral and injectable formulations.
Orforglipron
An oral small-molecule GLP-1 receptor agonist. It belongs in the GLP-1 resource ecosystem, but it should not be classified as a peptide drug.
3. Major Peptide Medicines Beyond GLP-1
Peptide medicine is much broader than obesity treatment. Peptide and peptide-like therapeutics are used across endocrinology, bone disease, gastrointestinal disorders, reproductive medicine, oncology and other fields.
| Peptide / peptide class | Therapeutic area | Resource topics |
|---|---|---|
| Pramlintide | Amylin analog / diabetes | Glucose control, appetite, post-meal glucose, combination with insulin |
| Tesamorelin | Growth-hormone-releasing factor analog | HIV-associated lipodystrophy, abdominal fat, IGF-1, limitations and safety |
| Teriparatide | Parathyroid hormone analog | Osteoporosis, bone remodeling, fracture prevention and treatment duration |
| Abaloparatide | PTH-related peptide analog | Osteoporosis and bone formation |
| Calcitonin | Bone / calcium regulation | Calcitonin biology, osteoporosis and clinical uses |
| Desmopressin | Vasopressin analog | Water balance, diabetes insipidus, nocturnal enuresis and hyponatremia risk |
| Octreotide | Somatostatin analog | Acromegaly, neuroendocrine tumors and gastrointestinal indications |
| Lanreotide | Somatostatin analog | Acromegaly and neuroendocrine tumors |
| Pasireotide | Somatostatin receptor ligand | Cushing disease, acromegaly and metabolic adverse effects |
| GnRH agonists | Endocrinology / reproductive medicine / oncology | Leuprolide, triptorelin, goserelin and related medicines |
| Oxytocin | Obstetrics | Labor induction, uterine contraction and clinical safety |
↔ Swipe the table sideways to see all columns on mobile.
This list is intentionally selective rather than exhaustive. The hub should eventually develop dedicated pages for major peptide medicines by therapeutic class.
4. Research & Experimental Peptides
A large online market has developed around compounds marketed for longevity, recovery, wound healing, body composition, cognitive performance and "anti-aging." The scientific evidence varies enormously between compounds.
| Research peptide | Commonly investigated area | Evidence / regulatory reading point |
|---|---|---|
| BPC-157 | Gastrointestinal biology, tissue repair, inflammation, musculoskeletal research | Predominantly preclinical/early evidence; not established as an approved therapeutic for these uses |
| TB-500 / thymosin beta-4 fragment | Wound healing, tissue repair and angiogenesis research | Limited clinical evidence for marketed recovery claims; regulatory and quality questions are important |
| CJC-1295 | Growth-hormone / IGF-1 axis research | Limited clinical data; safety and quality concerns for compounded products have been identified by FDA |
| Ipamorelin | Growth-hormone secretagogue research | Limited evidence; FDA has identified safety concerns regarding certain compounded uses |
| GHK-Cu | Skin biology, wound healing and extracellular-matrix research | Different routes and formulations should not be treated as equivalent; injectable compounded use has regulatory safety considerations |
| AOD-9604 | Body composition / metabolic research | Clinical evidence is limited relative to approved obesity medicines |
| Thymosin alpha-1 | Immune modulation research | Investigational status and regulatory availability vary by country; evidence is indication-specific |
| LL-37 | Innate immunity / antimicrobial and tissue biology | Experimental; significant uncertainty exists around human safety and therapeutic benefit |
| MOTS-c | Metabolic signaling and mitochondrial research | Experimental peptide; human evidence remains limited |
| Epitalon | Aging and cellular biology research | Predominantly experimental; major longevity claims are not established clinical facts |
| KPV | Inflammation and intestinal biology research | Predominantly preclinical research |
FDA has specifically identified concerns involving several compounded peptide substances, including BPC-157, CJC-1295, ipamorelin, injectable GHK-Cu, AOD-9604, thymosin alpha-1, TB-500 and LL-37. These concerns include limited safety information, immunogenicity risks, peptide impurities and characterization problems for certain routes of administration.
5. The OneDayMD Peptide Evidence Framework
To make the hub easier to navigate, every peptide article can use the same evidence framework. These labels are an editorial navigation system, not a replacement for formal clinical evidence grading.
| Level | Meaning | Typical evidence |
|---|---|---|
| E5 | Established clinical therapy | Approved indication plus substantial human evidence, guidelines or major outcome data |
| E4 | Strong clinical evidence | High-quality randomized trials or substantial late-stage clinical development, but the specific use may not be approved |
| E3 | Human evidence, but limited | Small trials, observational studies, uncontrolled studies or mixed clinical findings |
| E2 | Early or preclinical evidence | Animal studies, laboratory studies, pharmacology, mechanistic research or early human development |
| E1 | Very limited evidence | Case reports, isolated observations or hypothesis-generating evidence |
| E0 | No meaningful clinical evidence | Theoretical claims, marketing claims or anecdotal assertions without credible supporting evidence |
6. GLP-1 & Peptide Safety Center
Approved medicine safety
Approved GLP-1 and related medicines have undergone regulatory review for defined indications. Their safety profiles should be discussed using the current official prescribing information rather than social-media summaries.
Future safety guides should cover:
- Gastrointestinal adverse effects
- Dehydration and related complications
- Gallbladder disease
- Pancreatitis questions
- Hypoglycemia when combined with certain diabetes therapies
- Drug interactions and delayed gastric emptying
- Pregnancy considerations
- Retinal and visual symptoms where relevant
- Muscle and lean-mass considerations during major weight loss
- Perioperative and anesthesia considerations
- Serious symptoms requiring urgent medical assessment
Compounded and unapproved GLP-1 products
Unapproved versions of semaglutide and tirzepatide are not reviewed by FDA for safety, effectiveness and quality in the same manner as approved products. FDA advises that compounded medicines should be used when a patient's medical needs cannot be met by an FDA-approved drug and that patients obtain prescriptions and use appropriately licensed pharmacies.
Research peptide safety
Research peptides create an additional layer of uncertainty because the product supplied to consumers may not have the same identity, purity, sterility, concentration or manufacturing controls expected for an approved medicine.
A strong peptide safety article should therefore analyze both the molecule and the product.
7. How to Evaluate a Peptide Before Believing a Claim
1. Identify the molecule
Confirm the exact peptide, sequence, formulation and intended mechanism.
2. Check regulatory status
Determine whether the product is approved, investigational or unapproved for the claimed use.
3. Check human evidence
Prioritize randomized trials and well-designed human studies over testimonials.
4. Separate indication from mechanism
A biochemical effect does not automatically prove a clinical benefit.
5. Examine route and dose
Topical, oral, subcutaneous and intravenous exposure can have very different evidence and safety profiles.
6. Examine product quality
Purity, sterility, identity, storage and manufacturing controls matter.
8. GLP-1 & Peptide Topics We Will Build
GLP-1 Fundamentals
What GLP-1 is, how receptor agonists work, and how incretin biology affects appetite and glucose metabolism.
Semaglutide
Complete evidence guide covering diabetes, obesity, cardiovascular outcomes, formulations and safety.
Tirzepatide
GIP + GLP-1 biology, efficacy, safety, comparisons and emerging indications.
GLP-1 Muscle & Body Composition
Lean mass, protein, resistance training, sarcopenia risk and body-composition monitoring.
GLP-1 Side Effects
Common, uncommon, urgent and emergency symptoms organized by clinical relevance.
GLP-1 vs GIP/GLP-1
Understanding receptor biology and the differences between single and dual incretin approaches.
Retatrutide
Triple agonism, Phase 3 evidence, metabolic effects and regulatory development.
CagriSema
Semaglutide + cagrilintide and the emerging amylin/incretin combination strategy.
Amylin Peptides
Pramlintide, cagrilintide and the biology of appetite, gastric emptying and glucose regulation.
Growth-Hormone Peptides
Tesamorelin, CJC-1295, ipamorelin and the difference between approved therapy and experimental secretagogues.
Regenerative Peptides
BPC-157, TB-500, GHK-Cu and related tissue-repair claims reviewed against human evidence.
Longevity Peptides
MOTS-c, Epitalon and other experimental longevity claims separated from established clinical medicine.
Peptides for Skin
Cosmetic peptides, collagen-related peptides and medically studied peptide compounds.
Peptides for Bone Health
Teriparatide, abaloparatide, calcitonin and the biology of bone remodeling.
Peptides & Cancer
Separate established peptide-based medicines from experimental peptide approaches in oncology.
Peptide Drug Interactions
How peptide medicines may interact with insulin, diabetes drugs and other therapies.
9. GLP-1 & Peptide Comparison Tools
A major goal of the hub should be to turn the content library into practical comparison tools rather than a collection of disconnected articles.
| Tool | Purpose |
|---|---|
| GLP-1 Selector | Compare medicines by indication, mechanism, formulation, dosing frequency, outcome evidence and safety considerations. |
| Peptide Evidence Matrix | Compare each peptide by E0–E5 evidence level, human trials, regulatory status and therapeutic target. |
| Peptide Safety Checker | Identify whether a peptide is approved, investigational, unapproved or subject to specific regulatory concerns. |
| Clinical Trial Tracker | Track Phase 1–3 development of emerging obesity, metabolic and peptide medicines. |
| GLP-1 Muscle Calculator | Track protein intake, resistance training and body-composition changes during weight reduction. |
| Peptide A–Z Directory | One searchable index covering established medicines and experimental compounds. |
10. Peptide A–Z Quick Directory
11. Regulatory & Research Resources
Regulatory status should be checked using primary regulatory sources whenever possible. FDA's Drugs@FDA provides approved-drug information, labels, approval history and reviews.
FDA Resources for Information on Approved Drugs
FDA: Bulk Drug Substances That May Present Significant Safety Risks
12. GLP-1 & Peptide Research: What We Will Track
The resource hub should be updated as new evidence emerges in:
- Obesity and chronic weight management
- Type 2 diabetes
- Cardiovascular outcomes
- Kidney disease
- Metabolic dysfunction-associated steatotic liver disease
- Obstructive sleep apnea
- Muscle and body composition
- Osteoarthritis and pain
- Neurodegenerative and neurological research
- Inflammation and immune modulation
- Regenerative medicine
- Dermatology and wound healing
- Bone health
- Reproductive endocrinology
- Longevity and aging biology
13. Frequently Asked Questions
Are all GLP-1 drugs peptides?
No. Traditional GLP-1 receptor agonists such as semaglutide and liraglutide are peptide-based medicines. However, newer oral GLP-1 drugs can use a small-molecule rather than peptide structure.
Is tirzepatide a GLP-1 drug?
Tirzepatide activates both the GIP and GLP-1 receptors, so it is more precisely described as a dual GIP/GLP-1 receptor agonist.
Is retatrutide approved?
Retatrutide was still an investigational medicine as of September 2026 and should not be presented as an approved treatment.
Are BPC-157, TB-500 and CJC-1295 approved medicines?
They should not be treated as FDA-approved therapies for the popular wellness or recovery uses commonly promoted online. The regulatory status of individual compounds may differ across jurisdictions, so local regulatory databases should be checked.
Does a peptide with positive animal studies work in humans?
No conclusion can be made from animal data alone. Human pharmacokinetics, safety, dose, efficacy and clinically meaningful outcomes still need to be established.
What is the difference between a peptide medicine and a research peptide?
A peptide medicine has a defined pharmaceutical development and regulatory pathway for specific indications. A research peptide may have laboratory, animal or early human evidence without approval for routine clinical use.
Can peptide therapy be considered anti-aging treatment?
"Anti-aging" is a broad marketing category rather than a single established medical indication. Individual peptides should be evaluated according to specific clinical outcomes and human evidence rather than longevity claims alone.
14. The OneDayMD Approach to GLP-1 & Peptides
The purpose of this hub is not to turn every new molecule into a treatment recommendation. It is to make rapidly changing peptide science easier to understand.
Each major peptide should ultimately have its own evidence page covering: mechanism → clinical trials → indications → outcomes → safety → regulatory status → interactions → limitations → research gaps.
This structure allows readers to move from a headline or social-media claim to the underlying scientific evidence. It also creates a reusable framework for comparing established medicines with emerging therapies without confusing scientific plausibility with clinical proof.
.png)
.png)
.png)
Comments
Post a Comment